Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Levin Jeremy MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:18,248Price:$2.76
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Tardio JasonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Tardio JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Rona Jeffrey AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Rona Jeffrey AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Poole Robert MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Perone Thomas MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Perone Thomas MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Levin Jeremy MOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:700,000Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Friedman BartOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
Filings by filing date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Levin Jeremy MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:18,248Price:$2.76
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Tardio JasonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Tardio JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Rona Jeffrey AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Rona Jeffrey AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Poole Robert MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Perone Thomas MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:168,750Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Perone Thomas MichaelOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:28,125Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Levin Jeremy MOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:700,000Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Friedman BartOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 |
Tel: | N/A |
Website: | https://ovidrx.com |
IR: | See website |
Key People | ||
Jeremy Max Levin Chairman of the Board, Chief Executive Officer | Jeffrey Rona Chief Business and Financial Officer | Jason Tardio Chief Operating Officer |
Zhong Zhong Chief Scientific Officer | Thomas Michael Perone Chief Compliance Officer, General Counsel, Corporate Secretary | Meg Alexander Chief Strategy Officer | Manoj Malhotra Chief Medical Officer |
Business Overview |
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes. |
Financial Overview |
For the fiscal year ended 31 December 2023, Ovid Therapeutics Inc revenues decreased 74% to $392K. Net loss decreased 3% to $52.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other (Expenses) Income, Net - Balancing increase from $1.9M to $7.7M (income), SGA balancing decrease of 26% to $8.6M (expense). |
Employees: | 40 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $109.83M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.39M as of Dec 31, 2023 |
EBITDA (TTM): | -$58.71M as of Dec 31, 2023 |
Net annual income (TTM): | -$52.34M as of Dec 31, 2023 |
Free cash flow (TTM): | -$45.92M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,709,857 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |